Bausch Health Companies (BHC.TO) Stock Price
Bausch Health Companies Price
Over the last 19 years Bausch Health Companies grew revenue by 12.7% annually, reaching 10.45 B USD. Earnings per share have declined at 5.5% per year over the last 19 years. For Bausch Health Companies, the net margin of 1.5% is up versus -11.1% a few years ago. At today's price the dividend yield works out to roughly 20.12%. The dividend has grown at 26.5% per year over the past 4 years. The consensus 12-month price target for Bausch Health Companies is 7.27 USD, about 14.2% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.
Bausch Health Companies stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bausch Health Companies business model & stock analysis
Frequently asked questions about Bausch Health Companies
Bausch Health Companies Inc is primarily present in various countries and regions worldwide. The company has a significant presence in North America, including the United States and Canada, where it is headquartered. Additionally, Bausch Health operates in Europe, particularly in countries like Germany, France, Italy, and the United Kingdom. It also has a strong presence in Asia, with operations in China, Japan, and India. Bausch Health Companies Inc continues to expand its global reach and aims to serve patients and healthcare providers in diverse regions around the world.
Bausch Health Companies Inc, formerly known as Valeant Pharmaceuticals, operates under a diversified business model in the healthcare industry. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceuticals, medical devices, and over-the-counter products. Bausch Health primarily serves healthcare professionals and patients worldwide, offering products in various therapeutic areas such as eye health, dermatology, gastrointestinal health, and aesthetics. With a commitment to innovation and research, Bausch Health aims to improve patients' lives by providing high-quality, accessible healthcare solutions.
Bausch Health Companies Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Bausch Health Companies Inc in the market are Johnson & Johnson, Pfizer, Novartis, and Allergan.
Bausch Health Companies Inc, formerly known as Valeant Pharmaceuticals International Inc, is a renowned multinational pharmaceutical company headquartered in Laval, Canada. The company specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical products, including prescription drugs, over-the-counter medications, and medical devices. Bausch Health has a rich history dating back to its founding in 1959. Over the years, the company has experienced significant growth through successful acquisitions and strategic partnerships. Bausch Health now operates globally, serving patients in over 100 countries. Today, it remains committed to improving people's health and quality of life by providing innovative and accessible healthcare solutions.
Bausch Health Companies Inc has achieved several significant milestones. One notable achievement is its transformation and rebranding from Valeant Pharmaceuticals International Inc in 2018. Another milestone is the company's focus on enhancing its product portfolio and diversifying its revenue streams. Bausch Health has also made strides in research and development, introducing innovative pharmaceuticals and medical devices. Additionally, the company has demonstrated a commitment to sustainability and corporate social responsibility. Through these accomplishments, Bausch Health Companies Inc has established itself as a leading global pharmaceutical company, delivering value to patients, healthcare providers, and shareholders.
Bausch Health Companies Inc, a renowned pharmaceutical company, represents key values and a strong corporate philosophy. Guided by their mission to improve people's lives with healthcare products, Bausch Health is committed to innovation, integrity, and excellence. The company is focused on delivering cutting-edge medical solutions, ensuring patient well-being, and setting the highest standards for quality and safety. Bausch Health Companies Inc emphasizes collaboration, accountability, and ethical behavior, striving to foster an inclusive and diverse work environment. By constantly pushing the boundaries of medical innovation and maintaining their dedication to patient care, Bausch Health Companies Inc exemplifies their values of advancing healthcare for the betterment of society.
Analysts currently set an average price target of 7.27 USD for the Bausch Health Companies stock (median: 7.27 USD), implying +5.5 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Bausch Health Companies stock: 0 recommend buying, 5 holding and 4 selling. For 2026, analysts expect Bausch Health Companies to generate revenue of 10.77 B USD and earnings per share of 4.46 USD.
Converted at the current exchange rate, the Bausch Health Companies share trades at 5.71 EUR (6.36 USD).
The Bausch Health Companies share (BHC.TO) is listed on 6 stock exchanges, including: NYSE (BHC), SIX (Zürich) (VRX.SW), Toronto (BHC.TO), Frankfurt (BVF.F), München (BVF.MU), Düsseldorf (BVF.DU).
Bausch Health Companies Inc is a global healthcare company based in Canada. The company operates in three core business segments: Pharma, Bausch + Lomb, and Salix. The Pharma division focuses on the development and marketing of innovative drugs, including dermatology, neurology, urology, and gastroenterology products. Bausch + Lomb is a leading company in ophthalmology, offering both medical and optical products, such as contact lenses and surgical procedures. The Salix division specializes in the treatment of gastrointestinal disorders. Bausch Health has a strong network of distribution partners and invests heavily in research and development. The company has diversified its business into medical devices, aesthetics, and e-commerce, and uses social media and influencer marketing for promotion. Overall, Bausch Health aims to provide innovative products and services to promote health and well-being.
The expected revenue of Bausch Health Companies is 10.77 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Bausch Health Companies is 1.65 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bausch Health Companies is currently 1.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bausch Health Companies stock.
The price-to-sales ratio (P/S) of Bausch Health Companies is currently 0.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bausch Health Companies stock.
The Eulerpool Quality Score for Bausch Health Companies is 2/10.
The ISIN of Bausch Health Companies is CA0717341071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bausch Health Companies is A2JQ1X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bausch Health Companies is BHC.TO. The ticker symbol is used to trade Bausch Health Companies shares on the stock exchange.
Bausch Health Companies stock
Bausch Health Companies Peer Group
Bausch Health Companies Ticker
Bausch Health Companies FIGI
All fundamentals and in-depth analysis of Bausch Health Companies
Our stock analysis for Bausch Health Companies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bausch Health Companies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.